Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
PDO PIMCO Dynamic Income Opportunities Fund
BOCT Innovator U.S. Equity Buffer ETF™ October
BAC Bank of America Corp
YARIY Yara International ASA
XOM Exxon Mobil Corp
XLF Financial Select Sector SPDR® Fund
XFLT XAI Octagon Floating Rate & Alternative Income Term Trust
WPC WP Carey Inc
WMT WALMART STORES INC
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Closing Price
$1.26
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
658,616

10-day average volume:
1,304,867
658,616

Infosys (INFY) Inks $1.5B AI Deal With a Global Company

2:15 pm ET September 18, 2023 (Zacks) Print

Infosys INFY recently secured a new $1.5 billion deal with an undisclosed global company for a period of 15 years, according to an exchange filing last week. Through this agreement, INFY will provide an array of upgraded digital experiences and operational services based on its platforms and artificial intelligence (AI) solutions.

This marks the company’s second AI deal this month, with the first being a strategic and multi-year collaboration with STARK Group to drive its digital transformation based on Infosys' Topaz, a generative AI-based set of services, solutions and platforms.

In July 2023, INFY signed a $2 billion deal with an existing client, committing to deliver AI and automation services for a five-year duration.

Despite these AI achievements, Infosys is grappling with significant challenges, including a slowdown in digital transformation within the financial and related sectors. Furthermore, this Zacks Rank #4 (Sell) company has encountered delays in several large-scale deals due to drawn-out regulatory approvals and extended transition periods. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of the company have underperformed the Zacks Computer and Technology sector year to date. Shares of INFY have lost 0.3% year to date against the Zacks Computer and Technology sector’s rise of 43%.

Infosys Limited Price and Consensus

 

American Noble Gas Inc. Price and Consensus

Infosys Limited price-consensus-chart | Infosys Limited Quote

 

Infosys Faces Stiff Competition in the AI Landscape

The AI landscape is filled with big names like NVIDIA NVDA and Microsoft MSFT, which are partnering with Indian information technology (IT) companies that keep the potential of being the direct competitor of Infosys.

Recently, NVIDIA partnered with Indian giants like Reliance Industries and Tata Consultancy Services (“TCS”) to create generative AI based applications.

TCS also partnered with Microsoft to expand its AI capabilities, launch new AI enterprise solutions and provide AI training for its employees. Meanwhile, Wipro WIT, a key competitor of INFY, revealed plans to invest $1 billion in AI over the next three years.

In spite of tough competition and economic challenges, Infosys has found its niche in the AI market. The company sees growing potential for AI in the Retail, Communication and Original Equipment Manufacturing (OEM) sector.

New AI Opportunities Can Spark Fresh Growth for Infosys

In the Retail sector, there is intense focus on AI for accelerating digital transformation, cost efficiency and consolidation.

The Communication sector is facing slow growth due to budget cuts and delayed decision making. Infosys’ clients in this sector are increasingly prioritising cost-saving and vendor consolidation, while seeking innovative AI solutions to boost productivity.

INFY has also observed that its OEM clients are increasingly interested in revenue generation and efficient marketing services and they are turning to AI to optimize their operations.

Infosys aims to capitalize on this AI vacuum. It has reported having completed 80 generative AI projects for clients during the first quarter of fiscal 2024.

The company is also experiencing a surge in demand in areas, such as engineering, Internet of Things, supply chain, cloud computing, ERP and digital services, securing a robust deal pipeline despite the volatile business environment globally.

The latest forecast for worldwide IT spending by Gartner is also favorable for Infosys. Gartner anticipates worldwide spending on IT services to grow 8.8% year over year to $1.42 trillion this year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Microsoft Corporation (MSFT): Free Stock Analysis Report
 
American Noble Gas Inc. (INFY): Free Stock Analysis Report
 
Wipro Limited (WIT): Free Stock Analysis Report
 
NVIDIA Corporation (NVDA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.